BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3549325)

  • 1. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
    Joubert PH; Foukaridis GN; Bopape ML
    Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?
    Joubert PH; Venter HL; Foukaridis GN
    Br J Clin Pharmacol; 1990 Sep; 30(3):391-6. PubMed ID: 2223417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
    Heinz G; Komjati M; Korn A; Waldhäusl W
    Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.
    Sels JP; Nauta JJ; Menheere PP; Wolffenbuttel BH; Nieuwenhuijzen Kruseman AC
    Br J Clin Pharmacol; 1996 Oct; 42(4):503-6. PubMed ID: 8904624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
    Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
    Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
    Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W
    Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Miglitol, a new alpha-glucosidase inhibitor.
    Sels JP; Huijberts MS; Wolffenbuttel BH
    Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
    Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
    J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
    Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
    Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the alpha-glucosidase inhibitor miglitol.
    Lembcke B; Diederich M; Fölsch UR; Creutzfeldt W
    Digestion; 1990; 47(1):47-55. PubMed ID: 2292349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus.
    Dimitriadis G; Hatziagellaki E; Alexopoulos E; Kordonouri O; Komesidou V; Ganotakis M; Raptis S
    Diabetes Care; 1991 May; 14(5):393-8. PubMed ID: 2060451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of miglitol and acarbose on starch digestion, daily plasma glucose profiles and cataract formation.
    Madar Z; Hazan A
    J Basic Clin Physiol Pharmacol; 1993; 4(1-2):69-81. PubMed ID: 8679512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099).
    Russell JC; Graham SE; Dolphin PJ
    Metabolism; 1999 Jun; 48(6):701-6. PubMed ID: 10381143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
    Johnson AB; Taylor R
    Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
    Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
    Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
    Axen KV; Li X; Sclafani A
    Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].
    Kuboyama N; Hayashi I; Yamaguchi T
    Nihon Yakurigaku Zasshi; 2006 Mar; 127(3):223-32. PubMed ID: 16651808
    [No Abstract]   [Full Text] [Related]  

  • 19. Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
    Scott AR; Tattersall RB
    Diabet Med; 1988 Jan; 5(1):42-6. PubMed ID: 2964327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of alpha-inhibitors on blood glucose and insulin levels.
    Laube H; Federlin K; Hillebrand I
    Adv Exp Med Biol; 1988; 246():287-93. PubMed ID: 3074658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.